Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) – Investment analysts at Lifesci Capital issued their Q3 2024 earnings estimates for shares of Verve Therapeutics in a report released on Friday, August 9th. Lifesci Capital analyst C. Jubinville anticipates that the company will earn ($0.72) per share for the quarter. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.73) per share. Lifesci Capital also issued estimates for Verve Therapeutics’ Q4 2024 earnings at ($0.72) EPS.
Verve Therapeutics (NASDAQ:VERV – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.09. Verve Therapeutics had a negative net margin of 933.08% and a negative return on equity of 35.20%. The business had revenue of $6.70 million during the quarter, compared to analyst estimates of $2.40 million. During the same period last year, the business posted ($0.87) earnings per share. Verve Therapeutics’s quarterly revenue was up 219.0% compared to the same quarter last year.
View Our Latest Report on Verve Therapeutics
Verve Therapeutics Stock Performance
VERV stock opened at $4.54 on Monday. The firm has a 50 day moving average price of $5.91 and a 200-day moving average price of $8.54. Verve Therapeutics has a 52-week low of $4.52 and a 52-week high of $20.12. The firm has a market capitalization of $384.17 million, a price-to-earnings ratio of -1.58 and a beta of 1.84.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the business. PNC Financial Services Group Inc. bought a new stake in Verve Therapeutics in the fourth quarter worth about $29,000. Newbridge Financial Services Group Inc. bought a new position in Verve Therapeutics in the 4th quarter valued at $30,000. Quest Partners LLC purchased a new stake in Verve Therapeutics in the fourth quarter worth $34,000. Nisa Investment Advisors LLC lifted its position in shares of Verve Therapeutics by 908.4% during the second quarter. Nisa Investment Advisors LLC now owns 7,714 shares of the company’s stock worth $38,000 after purchasing an additional 6,949 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in shares of Verve Therapeutics by 89.8% during the second quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock valued at $59,000 after purchasing an additional 5,723 shares during the period. 97.11% of the stock is owned by hedge funds and other institutional investors.
About Verve Therapeutics
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Featured Articles
- Five stocks we like better than Verve Therapeutics
- Basic Materials Stocks Investing
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Industrial Products Stocks Investing
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.